T 0156 hydrochloride - CAS 324572-93-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C31H29N5O7.HCl
Molecular Weight:
620.06
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
T 0156 hydrochloride is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5). T 0156 exhibits higher selectivity than sildenafil (IC50 = 0.23, 56 and > 63000 nM for T 0156 and 3.6, 29 and > 270 nM for sildenafil at PDE5, PDE6 and PDEs 1 - 4 respectively).
Brife Description:
PDE5 inhibitor
Purity:
≥99% by HPLC
Synonyms:
T 0156 hydrochloride, T 0156 HCl, T 0156, T-0156, T0156; 1,2-Dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride; SR-01000076180
MSDS:
Inquire
InChIKey:
RBJCBXAXUHCWBR-UHFFFAOYSA-N
InChI:
InChI=1S/C31H29N5O7.ClH/c1-18-13-19(7-11-32-18)16-36-27(31(38)42-5)25(20-14-22(39-2)28(41-4)23(15-20)40-3)21-8-12-35-29(26(21)30(36)37)43-17-24-33-9-6-10-34-24;/h6-15H,16-17H2,1-5H3;1H
Canonical SMILES:
CC1=NC=CC(=C1)CN2C(=C(C3=C(C2=O)C(=NC=C3)OCC4=NC=CC=N4)C5=CC(=C(C(=C5)OC)OC)OC)C(=O)OC.Cl
1.T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs.
Mochida H;Noto T;Inoue H;Yano K;Kikkawa K Eur J Pharmacol. 2004 Feb 6;485(1-3):283-8.
T-0156 (2-(2-methylpyridin-4-yl)methyl-4-(3,4,5-trimethoxyphenyl)-8-(pyrimidin-2-yl)methoxy-1,2-dihydro-1-oxo-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride) is a newly synthesized phosphodiesterase type 5 inhibitor, and its potency and selectivity are higher than those of sildenafil in an enzyme assay. In the present study with anesthetized dogs, we examined the effects of intravenous T-0156 or sildenafil on the pelvic nerve stimulation-induced penile tumescence and light-adapted flicker stimulation-induced electroretinogram, parameters of which are reported to be indicators for inhibition of phosphodiesterase type 5 and type 6, respectively. Both compounds potentiated the penile tumescence in a dose-dependent manner. T-0156 at 10 microg/kg and sildenafil at 100 microg/kg showed almost the same potentiating percentage (181.5+/-31.1% and 190.0+/-37.9%) in spite of the plasma concentration of T-0156 being about five times lower than that of sildenafil (16.7+/-1.6 and 78.8+/-5.3 ng/ml), indicating that the effect of T-0156 on tumescence is more potent than that of sildenafil. While the high dose of T-0156 (1000 microg/kg) reduced the amplitude and increased the latency of the electroretinogram positive wave, the effects of T-0156 were conversely weaker than those of sildenafil (reduction of amplitude; T-0156: 41.
2.Involvement of a NO-cyclic GMP-PKG signaling pathway in nitrous oxide-induced antinociception in mice.
Zhang Y;Quock LP;Chung E;Ohgami Y;Quock RM Eur J Pharmacol. 2011 Mar 11;654(3):249-53. doi: 10.1016/j.ejphar.2011.01.006. Epub 2011 Jan 14.
The antinociceptive effect of nitrous oxide (N(2)O) is dependent on nitric oxide (NO); however, the next step in the pathway activated by NO is undetermined. The present study was conducted to test the hypothesis that a N(2)O action involves sequential activation of NO synthase, soluble guanylyl cyclase and protein kinase G to induce an antinociceptive effect in mice. The antinociceptive responsiveness of male NIH Swiss mice to N(2)O was assessed using the acetic acid abdominal constriction test. Different groups of mice were pretreated with either saline, the NO scavenger 2-(4-carboxyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazolyl-1-oxy-3-oxide (carboxy-PTIO), the guanylyl cyclase-inhibitor 1H-[1,2,4]-oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ), the protein kinase G-inhibitor Rp-isomer of 8-(4-chlorophenylthio)-guanosine-3',5'-cyclic monophosphorothioate (Rp-8-pCPT-cGMPS) or the selective phosphodiesterase V-inhibitor 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride (T 0156). Vehicle (saline)-pretreated mice responded to N(2)O in a concentration-dependent manner. This antinociceptive effect was antagonized by systemic pretreatment with carboxy-PTIO and ODQ and central pretreatment with Rp-8-pCPT-cGMPS.
3.[3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
Corbin JD;Blount MA;Weeks JL 2nd;Beasley A;Kuhn KP;Ho YS;Saidi LF;Hurley JH;Kotera J;Francis SH Mol Pharmacol. 2003 Jun;63(6):1364-72.
Sildenafil (Viagra) potentiates penile erection by acting as a nonhydrolyzable analog of cGMP and competing with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of direct binding of radiolabeled sildenafil to PDE5 have not been determined. [3H]Sildenafil binding to PDE5 was retained when filtered through nitrocellulose or glass-fiber membranes. Binding was inhibited by excess sildenafil, 2-(2-methylpyridin-4-yl)methyl-4-(3,4,5-trimethoxyphenyl)-8-(pyrimidin-2-yl)methoxy-1,2-dihydro-1-oxo-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride (T-0156), 3-isobutyl-1-methylxanthine, EDTA, or cGMP, but not by cAMP or 5'-GMP. PDE5 was the only [3H]sildenafil binding protein detected in human lung extract. Using purified recombinant PDE5, [3H]sildenafil exchange dissociation yielded two components with t1/2 values of 1 and 14 min and corresponding calculated KD values of 12 and 0.83 nM, respectively. This implied the existence of two conformers of the PDE5 catalytic site. [3H]Sildenafil binding isotherm of PDE5 indicated KD was 8.3 to 13.3 nM, and low cGMP decreased the KD to 4.8 nM but only slightly increased Bmax to a maximum of 0.61 mol/mol-subunit.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 936449-28-4 PDE5 inhibitor 42

PDE5 inhibitor 42
(CAS: 936449-28-4)

PDE5 inhibitor 42 is a second-generation phosphodiesterase type 5 (PDE5) inhibitor (IC50 = 0.04 nM).

CAS 862189-96-6 Mirodenafil dihydrochloride

Mirodenafil dihydrochloride
(CAS: 862189-96-6)

Mirodenafil dihydrochloride is a newly developed oral phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.

CAS 224789-15-5 Vardenafil dihydrochloride

Vardenafil dihydrochloride
(CAS: 224789-15-5)

Vardenafil, also called as Levitra and Nuviva, is a phosphodiesterase inhibitor that is selective for PDE5 and PDE1 (IC50 = 0.7 and 180 nM, respectively).

CAS 77671-31-9 Enoximone

Enoximone
(CAS: 77671-31-9)

Enoximone is a selective phosphodiesterase III (PDE3) inhibitor. It can be used for the treatment of heart failure.

CAS 439083-90-6 Bay 60-7550

Bay 60-7550
(CAS: 439083-90-6)

Bay 60-7550 is a potent PDE2 inhibitor. It is 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5 PDE3B, PDE4B...

CAS 85416-75-7 (R)-(-)-Rolipram

(R)-(-)-Rolipram
(CAS: 85416-75-7)

(R)-(-)-Rolipram is a potent and cAMP-specific PDE4 inhibitor. It is 2.5-fold more potent than (+)-rolipram in inhibiting membrane-bound PDE 4.

CAS 171596-29-5 Tadalafil

Tadalafil
(CAS: 171596-29-5)

Tadalafil binds to PDE5 with KD of 2.4 nM.

CAS 330784-47-9 Avanafil

Avanafil
(CAS: 330784-47-9)

A phosphodiesterase (PDE5) inhibitor, used to treat erectile dysfunction.

Chemical Structure

CAS 324572-93-2 T 0156 hydrochloride

Quick Inquiry

Verification code

Featured Items